Seqirus Inc.


Global influenza vaccine manufacturer focused on seasonal and pandemic preparedness. Operates multiple manufacturing sites using cell-culture and egg-based production, develops adjuvanted and next-generation vaccine formulations, supports clinical development and regulatory processes, and conducts real-world evidence and surveillance-focused analyses.

Industries

N/A

Nr. of Employees

medium (51-250)


Patents

Amphipathic peptide

US-10500287-B2

View Details

Amphipathic peptide

US-10188744-B2

View Details

Amphipathic peptide

US-9744244-B2

View Details

Products

Adjuvanted trivalent influenza vaccine (indicated for older adults)

Inactivated, adjuvanted trivalent influenza vaccine indicated for active immunization against specified influenza strains in older adults.

Cell-culture-derived quadrivalent influenza vaccine

Inactivated cell-based quadrivalent influenza vaccine indicated for active immunization against specified influenza A and B strains for pediatric and adult populations.

FLUAD

Adjuvanted influenza vaccine offered by CSL Seqirus.

FLUAD TRIVALENT

FLUAD TRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine, approved for use in persons 65 years of age and older.

FLUCELVAX TRIVALENT

FLUCELVAX TRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine, approved for use in persons 6 months of age and older.


Services

Collaborative agreements, licensing, joint ventures and strategic investments to advance vaccine technologies and commercialization.

Provision of pre-pandemic and pandemic vaccine doses, reserved manufacturing capacity, and coordination with governments for emergency response.

Support for externally initiated research studies through medical affairs collaboration.

Medical information services for healthcare providers and dedicated channels for adverse event reporting.

Expertise Areas

  • Vaccine manufacturing (cell-culture and egg-based)
  • Fill-and-finish operations and scale-up
  • Pandemic preparedness and surge production
  • Adjuvanted vaccine formulation
  • Show More (6)

Key Technologies

  • Cell-culture vaccine production
  • Egg-based vaccine production
  • Oil-in-water emulsion adjuvants (antigen-sparing)
  • mRNA and next-generation vaccine platforms
  • Show More (5)

News & Updates

Announcement of expanded U.S. vaccine availability after completion of a manufacturing campaign.

RWE estimating ~19.8% relative vaccine effectiveness of cell-based quadrivalent vaccines versus standard egg-based vaccines for the 2023/24 U.S. season.

Multiple BARDA awards to support fill-and-finish and expansion of adjuvant reserves for national pre-pandemic stockpiles.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.